Xenon Pharmaceuticals (XENE) Restructuring Costs (2024 - 2026)

Xenon Pharmaceuticals (XENE) has 3 years of Restructuring Costs data on file, last reported at $7.8 million in Q1 2026.

• On a quarterly basis, Restructuring Costs rose 41.04% year-over-year to $7.8 million in Q1 2026; TTM through Mar 2026 was $29.1 million, a 36.52% increase from a year earlier, with the FY2025 full-year figure at $26.8 million, up 29.71% from the prior year.
• Restructuring Costs for Q1 2026 stood at $7.8 million, down from $8.5 million in the prior quarter.
• Over the last five years, Restructuring Costs for XENE reached as high as $8.5 million in Q4 2025 and fell as low as $4.6 million in Q3 2024.
• Historically, Restructuring Costs has averaged $6.1 million across 3 years, with a median of $5.7 million in 2024.
• On a YoY basis, Restructuring Costs climbed as much as 53.99% in 2025 and fell as far as 6.27% in 2025.
• Year by year, Restructuring Costs stood at $5.5 million in 2024, then soared by 53.99% to $8.5 million in 2025, then decreased by 8.59% to $7.8 million in 2026.
• Per Business Quant data, the three most recent Restructuring Costs figures were $7.8 million in Q1 2026, $8.5 million in Q4 2025, and $6.7 million in Q3 2025.